News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Evolutec Ltd To Stop Investing In rEV131 As Fails To Meet Trial Primary Endpoint
January 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Biopharmaceutical company Evolutec Group PLC said it will stop investing in its rEV131 product after it failed to its primary endpoint in its Phase II post-cataract inflammation trial.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Obesity
Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III
June 23, 2025
·
2 min read
·
Tristan Manalac
Depression
Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression
June 23, 2025
·
2 min read
·
Tristan Manalac
Diabetes
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
June 23, 2025
·
2 min read
·
Tristan Manalac
Obesity
Zealand’s GLP-1/GLP-2 Drug Elicits Over 11% Weight-Loss—With the Potential for More
June 20, 2025
·
2 min read
·
Tristan Manalac
